Products
Professional investors can benefit from FDA’s expertise in several ways, depending on the size and characteristics of their portfolios. For institutional investors, FDA has several propositions, including:
- Research: subscription-based access to FDA Consultancy, an online investment decision support tool for institutional investors that reflects the daily output of the FDA team. FDA Consultancy comprises the risk/return and sustainability assessment of more than 100 international blue chip companies. The macroeconomic module contains the analysis of relevant macroeconomic trends based on a flow-of-funds method. The findings of equity and macro analysis are clearly linked to different portfolio management styles through FDA model portfolios.
- Full Portfolio Advice: the most comprehensive of our services, includes access to FDA Consultancy, private consultation, statistical data and reporting. Advice is provided for both equity and fixed-income portfolios. Our clients include pension funds, asset managers, charity funds and family offices.
- Tailor-made services such as periodic company reports, FDA Sustainability Assessment, various information modules based on customer-specific criteria, and investment consultancy services for regulatory and governmental bodies.
Sample reports
FDA Investment Trends (16 Apr 2025)
KLA Company Analysis (4 Oct 2024)
Ashtead Group Company Analysis (2 Jan 2024)
Amazon Company Analysis (10 Jul 2023)